Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today a new study on the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the currently predominant Delta variant, has been published in the International Journal of Molecular Sciences. The peer-reviewed study is the result of a collaboration between virologists at the Friedrich-Alexander-Universität Erlangen- Nürnberg (FAU) and Marinomed as well as scientists from Ulm University Medical Center and the University Hospital Tuebingen who provided the patient-isolates of SARS-CoV-2 VOCs. In short, the study showed that iota-carrageenan was the most effective of the three carrageenans tested. At a concentration as low as 10 μg/ml, it was able to almost completely block virus replication in Calu-3 human lung cells for all SARS-CoV-2 strains tested, including the highly infectious delta variant.
Prof. Dr. Ulrich Schubert, Professor at the Institute of Clinical and Molecular Virology at the Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, and principal investigator of the study, said: “Earlier this year, we have shown that iota-carrageenan can neutralize SARS-CoV-2. With our new data, we demonstrate that iota-carrageenan is also effective against highly infectious VOCs including the currently dominant delta variant. Iota-carrageenan acts via a physical mode of action and non-specifically envelops respiratory viruses via electrostatic forces and thus prevents the interaction between the virus and the cell. Iota-carrageenan has no pharmacological, immunological or toxicological activity and is not absorbed or metabolized, which makes it a safe biologically inert antiviral that can be applied topically, e. g. as nasal spray, throat spray or lozenges. Our results indicate that iota-carrageenan might be effective for prophylaxis and treatment of SARS-CoV-2 infections independent of the present and potential future variants.”